Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

医学 风湿病 临床终点 内科学 安慰剂 临床试验 胃肠病学 免疫系统 代理终结点 免疫学 病理 替代医学
作者
Jing He,Jiali Chen,Miao Miao,Ruijun Zhang,Gong Cheng,Yifan Wang,Ruiling Feng,Bo Huang,Huijie Luan,Yuan Jia,Yuebo Jin,Xiaoying Zhang,Miao Shao,Yu Wang,Xia Zhang,Jing Li,Xiaozhen Zhao,Han Wang,Tian Liu,Xian Xiao
出处
期刊:JAMA network open [American Medical Association]
卷期号:5 (11): e2241451-e2241451 被引量:99
标识
DOI:10.1001/jamanetworkopen.2022.41451
摘要

Importance: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches. Objective: To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS. Design, Setting, and Participants: A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group superiority design from June 2015 to August 2017. Sixty patients, aged 18 to 70 years, were recruited from Peking University People's Hospital. Efficacy analyses were based on the intention-to-treat (ITT) principle. Data were analyzed from December 2018 to March 2020. Interventions: Patients with pSS were treated with LD-IL-2 or placebo for 12 weeks and accompanied by 12 weeks of follow-up. Main Outcomes and Measures: The primary end point was defined as a 3-point or greater improvement on the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) by week 24. The secondary end points included other clinical responses, safety, and changes of immune cell subsets at week 12 and 24. Results: Sixty patients with pSS were recruited, with 30 in the LD-IL-2 group (mean [SD] age, 47.6 [12.8] years; 30 [100%] women) and 30 in the placebo group (mean [SD] age, 51.0 [11.9] years; 30 [100%] women), and 57 completed the trial. More patients in the LD-IL-2 group (20 [66.7%]) achieved ESSDAI score reduction of at least 3 points than in the placebo group (8 [26.7%]) at week 24 (P = .004). There were greater resolutions of dryness, pain, and fatigue in the LD-IL-2 group than placebo group at week 12 (dryness: difference, -18.33 points; 95% CI, -28.46 to -8.21 points; P = .001; pain: difference, -10.33 points; 95% CI, -19.38 to -1.29 points; P = .03; fatigue: difference, -11.67 points; 95% CI, -20.65 to -2.68 points; P = .01). No severe adverse events were observed in either group. In addition, the LD-IL-2 group showed a significant decrease in infection compared with the placebo group (1 [3.3%] vs 9 [30.0%]; P = .006). Immunological analysis revealed that LD-IL-2 promoted an expansion of regulatory T cells and regulatory CD24highCD27+ B cells. Conclusions and Relevance: In this randomized clinical trial, LD-IL-2 was effective and well tolerated in patients with pSS, and it restored immune balance, with enhanced regulatory T cells and CD24highCD27+ B cells. Trial Registration: ClinicalTrials.gov Identifier: NCT02464319.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
WzJCW完成签到,获得积分20
1秒前
梦寐寤寐发布了新的文献求助10
1秒前
2秒前
王12完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
5秒前
skip发布了新的文献求助10
5秒前
5秒前
Ican发布了新的文献求助10
5秒前
5秒前
通过发布了新的文献求助10
6秒前
不安的问雁完成签到,获得积分20
6秒前
拜拜拜仁完成签到,获得积分10
6秒前
晨晨的应助被WSND采纳,获得50
8秒前
9秒前
10秒前
11秒前
orange发布了新的文献求助10
11秒前
11秒前
chris chen完成签到,获得积分10
11秒前
11秒前
哈哈哈哈发布了新的文献求助10
11秒前
beibei发布了新的文献求助10
11秒前
11秒前
12秒前
ying777完成签到,获得积分20
13秒前
13秒前
xl发布了新的文献求助10
14秒前
16秒前
充电宝的应助被ZB采纳,获得10
16秒前
17秒前
17秒前
Rina发布了新的文献求助10
17秒前
18秒前
JiaQi完成签到,获得积分10
19秒前
无敌黄金发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579325
关于积分的说明 21864493
捐赠科研通 7792494
什么是DOI,文献DOI怎么找? 3437087
关于科研通互助平台的介绍 2560652
邀请新用户注册赠送积分活动 2483937